These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33607781)

  • 21. Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
    Nakasya A; Hagiwara Y; Ikoma T; Kurioka Y; Matsumoto T; Yamamoto Y; Tsuduki T; Kajiwara T; Moriwaki T; Nishina T; Yamashita N; Hyodo I
    Int J Clin Oncol; 2022 Apr; 27(4):684-694. PubMed ID: 35089459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis.
    Li Y; Lu X; Lin Q; Li W
    J Int Med Res; 2020 Aug; 48(8):300060520943473. PubMed ID: 32762463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
    Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
    Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
    Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
    Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments.
    Duan J; Hao Y; Wan R; Yu S; Bai H; An T; Zhao J; Wang Z; Zhuo M; Wang J
    Thorac Cancer; 2017 May; 8(3):138-146. PubMed ID: 28304139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer.
    Guo Q; Zhang H; Li X; Quan X
    Biomed Res Int; 2022; 2022():9430952. PubMed ID: 36147633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
    Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
    BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Nanoparticle Albumin-Bound Paclitaxel (nab-PTX) Monotherapy Can Be Improved after Treatment with Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer: Long-Term Follow-Up and Updated Analysis of Two Previous Prospective Clinical Studies.
    Nakashima K; Umeda Y; Demura Y; Sonoda T; Tada T; Yamaguchi M; Anzai M; Kadowaki M; Oi M; Honjo C; Mitsui M; Waseda Y; Ishizuka T
    Oncology; 2024; 102(7):593-603. PubMed ID: 38290482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I Study of Combination Therapy With Weekly Nanoparticle Albumin-bound Paclitaxel and Cyclophosphamide in Metastatic Breast Cancer Patients.
    Ota D; Akatsuka S; Nishi T; Kato T; Takeuchi M; Tsuji M; Fukuuchi A
    Anticancer Res; 2019 Dec; 39(12):6903-6907. PubMed ID: 31810960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
    Yamamoto S; Maeda N; Nagashima Y; Kubo H; Sato Y; Matsui H; Inoue Y; Shindo Y; Kanekiyo S; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yoshino S; Hazama S; Oka M; Nagano H
    Breast Cancer; 2017 Nov; 24(6):783-789. PubMed ID: 28439763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of nanoparticle albumin-bound paclitaxel in taxane-pretreated metastatic breast cancer patients.
    Xiong W; Xu T; Liu X; Zhang L; Yuan Y
    Cancer; 2024 Apr; 130(S8):1488-1498. PubMed ID: 38271397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Layer-by-layer assembly of hierarchical nanoarchitectures to enhance the systemic performance of nanoparticle albumin-bound paclitaxel.
    Ruttala HB; Ramasamy T; Shin BS; Choi HG; Yong CS; Kim JO
    Int J Pharm; 2017 Mar; 519(1-2):11-21. PubMed ID: 28069389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced performance of macrophage-encapsulated nanoparticle albumin-bound-paclitaxel in hypo-perfused cancer lesions.
    Leonard F; Curtis LT; Yesantharao P; Tanei T; Alexander JF; Wu M; Lowengrub J; Liu X; Ferrari M; Yokoi K; Frieboes HB; Godin B
    Nanoscale; 2016 Jul; 8(25):12544-52. PubMed ID: 26818212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer.
    He MM; Wang F; Jin Y; Yuan SQ; Ren C; Luo HY; Wang ZQ; Qiu MZ; Wang ZX; Zeng ZL; Li YH; Wang FH; Zhang DS; Xu RH
    Cancer Sci; 2018 Nov; 109(11):3575-3582. PubMed ID: 30281875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of combination therapy with nanoparticle albumin-bound paclitaxel and cyclophosphamide in patients with metastatic or recurrent breast cancer.
    Kutomi G; Ohmura T; Satomi F; Maeda H; Shima H; Kameshima H; Okazaki M; Masuoka H; Sasaki K; Hirata K
    Int J Clin Oncol; 2015 Jun; 20(3):474-9. PubMed ID: 25073954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel as Neoadjuvant Chemotherapy in Breast Cancer Patients].
    Kang Y; Shiraki E; Tsuyuki S
    Gan To Kagaku Ryoho; 2019 Sep; 46(9):1427-1431. PubMed ID: 31530783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group.
    Tsuyuki S; Senda N; Kanng Y; Yamaguchi A; Yoshibayashi H; Kikawa Y; Katakami N; Kato H; Hashimoto T; Okuno T; Yamauchi A; Inamoto T
    Breast Cancer Res Treat; 2016 Nov; 160(1):61-67. PubMed ID: 27620884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis.
    Tan H; Hu J; Liu S
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):268-277. PubMed ID: 30600739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma.
    Huang Y; Liang W; Yang Y; Zhao L; Zhao H; Wu X; Zhao Y; Zhang Y; Zhang L
    BMC Cancer; 2016 Jul; 16():464. PubMed ID: 27411683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.